Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management.
Bellmunt J, Valderrama BP, Puente J, Grande E, Bolós MV, Lainez N, Vázquez S, Maroto P, Climent MÁ, Garcia Del Muro X, Arranz JÁ, Durán I. Bellmunt J, et al. Among authors: climent ma. Crit Rev Oncol Hematol. 2022 Jun;174:103683. doi: 10.1016/j.critrevonc.2022.103683. Epub 2022 Apr 16. Crit Rev Oncol Hematol. 2022. PMID: 35439541 Free article. Review.
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J; Spanish Oncology Genitourinary Group. Bellmunt J, et al. Among authors: climent ma. Cancer. 2002 Aug 15;95(4):751-7. doi: 10.1002/cncr.10762. Cancer. 2002. PMID: 12209718 Free article. Clinical Trial.
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J; Spanish Oncology Genito Urinary Group Study Group. Carles J, et al. Ann Oncol. 2007 Aug;18(8):1359-62. doi: 10.1093/annonc/mdm160. Ann Oncol. 2007. PMID: 17693649 Free article. Clinical Trial.
Sorafenib in renal cell carcinoma.
Arranz JÁ, Climent MÁ, González-Larriba JL, León L, Maroto JP. Arranz JÁ, et al. Among authors: climent ma. Crit Rev Oncol Hematol. 2011 Nov;80(2):314-22. doi: 10.1016/j.critrevonc.2011.01.008. Epub 2011 Mar 21. Crit Rev Oncol Hematol. 2011. PMID: 21419641 Review.
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, González del Alba A, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C. Garcia-Donas J, et al. Among authors: climent ma. Lancet Oncol. 2011 Nov;12(12):1143-50. doi: 10.1016/S1470-2045(11)70266-2. Epub 2011 Oct 17. Lancet Oncol. 2011. PMID: 22015057
Recommendations for the optimal management of early and advanced urothelial carcinoma.
Castellano D, Carles J, Esteban E, Trigo JM, Climent MÁ, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz JÁ, Bellmunt J. Castellano D, et al. Among authors: climent ma. Cancer Treat Rev. 2012 Aug;38(5):431-41. doi: 10.1016/j.ctrv.2011.10.004. Epub 2011 Nov 23. Cancer Treat Rev. 2012. PMID: 22116017 Review.
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MA, Piulats JM, Sánchez-Hernández A, Arranz JÁ, Cassinello J, García-Donas J, González del Alba A, León-Mateos L, Mellado B, Méndez-Vidal MJ, Pérez-Valderrama B; Spanish Oncology Genitourinary Group. Climent MA, et al. Crit Rev Oncol Hematol. 2012 Sep;83(3):341-52. doi: 10.1016/j.critrevonc.2012.01.002. Epub 2012 Jan 29. Crit Rev Oncol Hematol. 2012. PMID: 22285697
118 results